Evidence map›Paper›PMID 38642097›Full record

ArticleAnalytical and bioanalytical chemistry2024

Development of an SI-traceable N-terminal pro-B-type natriuretic peptide certified reference material using structure-based impurity-corrected isotope dilution mass spectrometry approaches.

Peng Xiao, Jinchao Chen, Peize Wu, Weifei Zhang, Zepeng Sun, Jian Ma, Hongmei Li

Abstract read
PubMed Publisher
In one paragraph

Article in Analytical and bioanalytical chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Peng XiaoNational Institute of Metrology, Beijing, 100029, China. xiaop@nim.ac.cn.
Jinchao ChenNational Institute of Metrology, Beijing, 100029, China.
Peize WuNational Institute of Metrology, Beijing, 100029, China.
Weifei ZhangNational Institute of Metrology, Beijing, 100029, China.
Zepeng SunNational Institute of Metrology, Beijing, 100029, China.
Jian MaDepartment of Immunology, Harbin Medical University, Harbin, 150081, China.
Hongmei LiNational Institute of Metrology, Beijing, 100029, China. lihm@nim.ac.cn.

Funding

National Institute of Metrology Fundamental Research Project AKYZD2115-2National Key Research and Development Program of China 2019YFF0216505National Key Research and Development Program of China 2022YFF0710303
6 · The paper itself

Abstract

N-Terminal pro-B-type natriuretic peptide (NT-proBNP) is a pivotal biomarker for the diagnosis and prognosis of heart failure (HF). However, no SI-traceable certified reference material (CRM) or reference measurement procedure (RMP) is available for this biomarker, and so clinical testing results obtained in different laboratories cannot be traced to a higher-order standard, leading to incomparable measurements. Protein hydrolysis and protein cleavage isotope dilution mass spectrometry (AAA-IDMS and PepA-IDMS) were used to develop a CRM. Structurally related impurities were identified by high-resolution mass spectrometry. The quantitative AAA-IDMS results were corrected according to the amino acid compositions of the impurities. Using PepA-IDMS, two peptides from the proteolyzed product were confirmed as signature peptides. To obtain traceable and accurate results, the signature peptides were quantified using impurity-corrected AAA-IDMS. The candidate NT-proBNP solution was denatured and enzymatically digested using the Glu-C endoproteinase. The released signature peptides were measured using an isotopic dilution approach. The homogeneity and stability of the candidate CRM were characterized, and their uncertainties were combined with the value assignment process. The developed CRM can be considered a unique SI-traceable NT-proBNP reference material and is expected to be used as a primary calibrator for matrix NT-proBNP CRM development.

Indexed as

Mass SpectrometryNatriuretic Peptide, BrainPeptide FragmentsReference StandardsBiomarkersIndicator Dilution TechniquesBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Heart failure biomarkerIsotope dilution mass spectrometryN-Terminal pro-B-type natriuretic peptideReference materialSI-traceableStructural-related impurity

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.